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compression fractures in Spain. METHODS: Two alternative
models will be introduced here. One standard contingent valua-
tion model (CV), where mean values for willingness to pay
(WTP) for the treatment with BKP are obtained through a survey
including patients with primary osteoporosis. A new quality of
life adjusted wages model (QAW) is also introduced here. The
main assumption of this model is that a disease acts on individu-
als as a tax, where wages are deﬂected here by a quality of life
index (EuroQol 5-D) in the same way as a proportional income
tax. The burden of disease is given by this model in terms of an
equivalent variation or welfare changes in monetary terms. The
model avoids different kind of biases introduced in many times
by the CV approach and is a faster and more rigorous tool to ﬁnd
welfare changes determined by diseases and their medical treat-
ments. RESULTS: A sample of 168 individuals who had been
asked about their WTP for BKP was used to develop the CV
model. A mean value for WTP of €3909 is revealed by the
sample. A sample of 300 patients 21 years of age or older and
both genders coming from a clinical trial designed by Kyphon,
was used to develop QAW model, here is that BKP determines in
the ﬁrst month a yearly welfare gain of €2665, increased to
€3311 after 12 months. CONCLUSIONS: The results using CV
models and QAW model are similar in the ﬁrst year of life. It can
be explained through a temporal downward bias introduced by
WTP responses that means that a patient doesn’t include in his
personal WTP an estimation of his life expectancy.
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OBJECTIVES: Evidence-based guidelines recommend treatment
for postmenopausal women with osteoporosis to prevent frac-
tures. The study aims at determining since when this was known
and whether the utilization of bisphosphonates in Germany from
this point onward was adequate and to what extent health gains
might have been foregone due to a limited use of bisphosphonates.
METHODS: To determine since when the beneﬁcial effect (pre-
vention of fractures) was known, cumulative meta-analyses of
randomized controlled trials derived from systematic reviews
were conducted. The evidence-base was considered as established,
when a signiﬁcant (5%-level) reduction of fractures was observed
in trial populations combined inmeta-analysis compared to thera-
pies without bisphosphonates. Utilization ﬁgures for bisphospho-
nates and epidemiological estimates where taken from published
sources. RESULTS: The hip/femur fracture risk was signiﬁcantly
lower if treatment included bisphosphonates compared to treat-
ment without bisphosphonates (RR 0.62; 95%-CI 0.40–0.97 / RR
0.45; 95%-CI 0.23–0.90). In principal, this was known since
1995/1996. Utilization of bisphosphonates in 1996 was sufﬁcient
for the continuous treatment of about 8,200 patients (440,000
patients in 2006). About 1.6 to 1.9million patients annuallymight
have beneﬁtted from treatment. About 22,800 fractures might
thus have been avoided, had all patients with potential beneﬁt
continuously received bisphosphonates since 1996/1997. CON-
CLUSIONS: The delay in the wider use of bisphosphonates for
osteoporosis treatment has resulted in a considerable loss of
potential health gains in terms of avoided fractures. An arguable
lack of evidence for the expected beneﬁt from bisphosphonate
therapy does not sufﬁciently explain this ﬁnding. Other factors
(e.g. cost considerations) might have contributed to this result.
Limitations of the present analysis are primarily associated with
uncertainties of epidemiological estimates and the application of
study results to the entire patient population.
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ANTI-TUMOUR NECROSIS FACTOR-&ALPHA; INHIBITOR
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OBJECTIVES: Real-world data on long-term dosing patterns
in ﬁrst time anti-TNFa inhibitor treated rheumatoid arthritis
patients is lacking. Such data are important for the calculation
of treatment cost, especially for products where the label
allows for varying doses and frequency of administrations.
METHODS: The Dutch Rheumatoid Arthritis Monitoring
(DREAM) project is a longitudinal, multi-centre patient register
monitoring biologic DMARD usage in clinical practice since
February 2003. Patients meeting the Dutch reimbursement
criteria (DAS28 > 3.2, inadequate response to 2 DMARDs
including methotrexate, no prior bDMARDs) were assessed at
three-month intervals for 48 months. Dosing was determined by
the attending rheumatologist guided by the recommended
labelled doses (adalimumab 40 mg every other week, etanercept
25 mg twice weekly, inﬂiximab 3 mg/kg at week 0, 2, 4, 8 and
every 8 weeks thereafter). Mean dose was calculated based on
the actual dose prescribed at each visit and the change over time
evaluated for each anti-TNFa. RESULTS: The mean baseline
doses for adalimumab (N = 374), etanercept (N = 432) and
inﬂiximab (N = 325) were 39.9 mg/two weeks, 24.2 mg twice
weekly, and 3.4 mg/kg per eight weeks. Mean baseline DAS28
and HAQ ranged from 5.2–5.4 and 1.3–1.4, respectively.
Nearly one-third of inﬂiximab patients were prescribed greater
than the labelled dose at baseline (32%, N = 105) compared to
2.5% and 0.2% for adalimumab and etanercept. At 12, 24, and
48 months follow-up, mean doses were: adalimumab, 41.5,
43.3, and 45.7 mg/two weeks (42 months); etanercept, 24.0,
24.9, and 23.9 mg twice per week (45 months); inﬂiximab, 4.3,
4.9, and 4.9 mg/kg/every eight weeks (48 months). Mean doses
in inﬂiximab patients prescribed greater than the recommended
labelled dose at baseline were 4.7, 5.2, and 5.6 mg/kg at the
same follow-up intervals. CONCLUSIONS: Longitudinal
patient registry data from The Netherlands show a marked and
continued dose escalation in RA patients prescribed inﬂiximab
as a ﬁrst-line anti-TNFa when compared to either adalimumab
or etanercept.
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OBJECTIVES: To determine the co-morbidity and direct cost
inﬂuence in patients with osteoporosis in a Spanish population
setting in under usual medical practice. METHODS: We per-
formed a transversal retrospective study realized beginning from
registers of subjects older than 44 years appertaining to seven
centers of primary care (year 2,006). A control group without
osteoporosis was formed. Main measures: general (age, gender),
general co-morbidities and speciﬁc (ICPC-2), Charlson index
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(patient severity), biochemical parameters (lipids, glucose, etc.)
and cost model. The general morbidity charge was quantiﬁed
beginning from Adjusted Clinical Groups (http://www.acg.
jhph.edu). The program provides the utilization bands of
resources (RUB, co-morbidities levels). It was considered ﬁxed/
semi-ﬁxed cost structure/salary/services) and variable one
(diagnostics/therapeutical requests, referrals, drugs). Logistical
regression analysis was effected (procedure: enter) and the cova-
riance (ANCOVA) for the correction of the models (procedure:
Bonferroni), according to the recommendations of Thompson-
Barber. Program SPSSWIN; p < 0.05. RESULTS: A total of
35,207 subjects 44 years were studied, 10.9% (95% CI: 13.3–
15.1%) show osteoporosis (average aged: 62.5  11.8 years;
woman: 94.4%). The patients with osteoporosis presented main
general morbidity (RUB: 2.9  0.6 vs. 2.7  0.7; episodes:
8.0  4.5 vs. 5.7  3.7), total cholesterol (213.2  36.1 vs.
208.9  30.9 mg/ml), visits (12.9  10.9 vs. 9.6  9.3) and
polypharmacy (41.2% vs. 22.2%), p < 0.001. The osteoporosis
had an independent association in presence from fracture
(OR = 1.4), ﬁbromyalgia (OR = 1.3), dyslipidemia (OR = 1.3),
asthma (OR = 1.2), depression (OR = 1.2) y thyroid diseases
(OR = 1.2), p < 0.001. The average unitary/total cost adjusted
for year, gender and RUB was €1387.28 vs. €808.98; and the
pharmaceutical of €1018.62 vs. €522.33; p < 0.001. All compo-
nents of outpatient management costs were signiﬁcantly higher in
the osteoporosis group. Eighteen percent of the total cost was
related to drugs. CONCLUSIONS: Patients with osteoporosis
presented a high morbidity (general) and speciﬁc one, existing
differences of gender (women), producing a high consume of
sanitary recourses.
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COLLECTING REAL DATA FROM REAL PATIENTS
Wade AG, Crawford G
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OBJECTIVES: 1) To assess the willingness of patients to
provide information about medical treatment, and 2) to prac-
tically demonstrate that useful information can be collected
METHODS: Public acceptability towards reporting side-effects
and efﬁcacy of medical treatments was assessed by 1) online
questionnaire, and 2) assisted questionnaire. Results from the
ﬁrst 137 respondents to the on-line questionnaire and 115
respondents to the assisted questionnaire are reported. A total
of 110 leaﬂets were distributed inviting patients to log on to a
dedicated website and provide information on post-vaccination
symptoms. Information was gathered on the day of vaccina-
tion, two days later and at day eight. RESULTS: A total of
94% of interviewees were aware of the possibility of side
effects. Of interviewees who had personal experience of side
effects, 39% did not report them. The perceived principle
conduit (81%) for reporting was to the physician. The moti-
vating factors for reporting adverse drug reactions (ADR’s) in
order of frequency was stated to be, ensuring medical safety of
others (31%), ensuring their own future good health (28%) the
advice of pharmacists/nurses (12%) and ﬁnancial incentives if
available (7%). A total of 73% reported willingness to report
side-effects via the Internet. A total of 110 leaﬂets were distrib-
uted at an inﬂuenza vaccine clinic inviting patients to log on to
an interactive website and provide information. 73 (66%) reg-
istered on the day of vaccination, 70 (96%) responded at day
two and 66 (90%) at day eight. Statistics on pain and discom-
fort demonstrate that while the majority of patients have no
pain, 8% experienced signiﬁcant discomfort and 3% pain for
greater than one hour. Of side effects reported, none required
medical attention and the majority were self-limiting. CON-
CLUSIONS: We have conﬁrmed that patients are willing to
provide information about medical treatment via an interactive
web-based system. This technique has potential for the conduct
of naturalistic studies and for post-marketing surveillance.
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OBJECTIVES: When conducting systematic reviews of ran-
domised controlled trials (RCTs), an important step is to criti-
cally assess the quality of included studies. As emphasis on sound
trial design has increased over the years, we sought to establish
how quality of studies included in systematic reviews is associ-
ated with the publication year of those studies. METHODS: We
analysed the studies included in 4 large, clinical systematic
reviews of randomised controlled trials conducted by Heron in
the last 6 months. These covered 4 disease areas: oncology,
hyperlipidaemia, anaesthesia, and serious bacterial infection. The
data extracted included a critical appraisal of study quality based
on means of quality scales. These were the Jadad scale, which
assesses randomisation, blinding, patient attrition and reporting
quality and gives a score from 1 (low) to 5 (high), and the
allocation concealment grade, which assess whether allocation to
treatment was adequately concealed. We analysed trends in both
Jadad score and allocation concealment grade by year of publi-
cation, with stratiﬁcation by disease area. RESULTS: A total of
291 trials were included in the analyses from the 4 reviews. Most
of these were carried out between 1981–2008. The average
overall Jadad score was 2.3, suggesting low overall trial quality.
Jadad score increased from a mean of 1.4 over the period 1981–
1986 to 2.9 over the period 2001–2006. Furthermore there was
an increase in the percentage of high quality (Jadad score 4–5)
trials—from 6% in 1981–1986 to 36% in 2001–2006. Only 3%
of RCTs from the period 1981–1990 recorded adequate alloca-
tion concealment; this increased to 26% over the period 1996–
2006. CONCLUSIONS: There was an observable increase in
trial quality over the period analysed. However, the mean Jadad
score, and the proportion of trials with adequate concealment of
allocation remained low, even by 2006, indicating the need for
continued attention to study quality.
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OVERCOMINGTHE FINAL HURDLE: COMMUNICATINGTHE
COST EFFECTIVENESS OF A NEW DRUG
Shannon PR, Beard S
RTI Health Solutions, Manchester, UK
OBJECTIVES: Although effective post-approval communication
is vital in building awareness in the clinical community of newly
approved and recommended drugs, the development of such
communications can often have a lower priority than supporting
a drug through its formal regulatory submission. In this study we
considered how standard Excel-based cost effectiveness models
could be adapted to enhance communication of economic value.
METHODS: Even with a clear and positive regulatory approval
and recommendation, from groups such as National Institute for
Health and Clinical Excellence (NICE), an additional hurdle is
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